JUN 10, 2019 10:01 AM PDT

Novel Treatments for Auto-immune Disorders

WRITTEN BY: Nouran Amin

A recent research study examined a library of almost 300,000 small molecules to search for a molecule that may be a potential target for the human GMP-AMP synthase (cGAS)—an enzyme that can detect and bind to cytosolic DNA and initiating a chain reaction leading to immune activation with the result of the destruction of the DNA-shedding pathogen.

Through their initial screening, researchers were able to identify two molecules that showed some activity against cGAS.

“The hits from library compounds were a great starting point, but they were not potent enough,” said postdoctoral associate Lodoe Lama. “So we used them as molecular scaffolds on which to make improvements, altering their structures in ways that would increase potency and also reduce toxicity.”

In collaboration with Tri-Institutional Therapeutics Discovery Institute, scientists created three compounds that inhibited cGAS activity in human cells. Further analytical studies by researchers at Memorial Sloan Kettering Cancer Centre showed that compounds block cGAS activation by wedging into a critical pocket.

The significance of inhibiting cGAS would be of critical therapeutic relevance to those with autoimmune diseases who have few treatment options. Currently, compounds are being optimized for prospective use in patients particularly those diagnosed with a rare genetic disease called Aicardi-Goutières syndrome. Individuals with Aicardi-Goutières syndrome have an abnormal accumulation of cytosolic DNA that activates cGAS and can lead to serious neurological problems.

“This class of drug could potentially also be used to treat more common diseases, such as systemic lupus erythematosus, and possibly neurodegenerative diseases that include inflammatory contributions, such as Parkinson’s disease,” adds Thomas Tuschl, Ph.D.

Findings of the study, as reported in Nature Communications, sheds light on the causes of autoimmunity.

“Scientists will now have simple means by which to inhibit cGAS in human cells,” concluded Lama. “And that could be immensely useful for studying and understanding the mechanisms that lead to autoimmune responses.”

Source: Drug Target Review

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Possible Therapeutic for Duchenne Muscular Dystrophy (DMD)
Individuals diagnosed with Duchenne muscular dystrophy (DMD) face few treatment options. DMD is a progressive muscle weakness and degeneration with loss of...
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Drug Reverses Effects of Alcohol on the Brain
Recently, researchers have identified a drug that could help reverse the damaging effects of heavy alcohol consumption on the regeneration of neurons (brai...
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Chemopreventative Drug Targets H. Pylori Infections
A chemopreventative drug being tested for its ability to inhibit the production of cell growth in multiple types of cancer was found to act directly on the...
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Drug for Huntington Disease Successfully Lowers Culprit Protein
In a study published in the New England Journal of Medicine, a drug for the first time was shown to successfully lower the abnormal protein that causes the...
JUN 20, 2019
Microbiology
JUN 20, 2019
Vulnerability in Famously Hard-to-Target Viruses is Identified
The cold virus is famously difficult to target with drugs because it can mutate rapidly....
JUN 20, 2019
Drug Discovery
JUN 20, 2019
Sickle cell drug promising in clinical trial
UConn School of Medicine researchers report that an investigational drug used for treating for the sickle cell disease has shown promising results in early...
Loading Comments...